Are payers treating orphan drugs differently? by Joshua P. Cohen, Abigail Felix

Subjects: “…orphan drugs…”
Get full text

Current Problems in Provision of Orphan Drugs and Ways to Solve Them by Alexei S. Kolbin, Roman A. Gapeshin, Stanislav M. Malyshev

Subjects: Get full text

Analysing criteria for price and reimbursement of orphan drugs in Spain by Xavier Badia, Alicia Gil, José Luis Poveda-Andrés, John Shepherd, Marina Tort

Subjects: “…Orphan Drugs…”
Get full text

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS by Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev

Subjects: Get full text

Current Situation, Trend, and Opportunity of Applying Blockchain to the Supply Chain of Orphan Drugs by LI Wenyan, YOU Yile, WU Jindong, LI Xinrui, JIANG Yunyun, WANG Shengfeng

Subjects: Get full text

Quantifying the persisting orphan-drug shortage public health crisis in the United States by Szymon Jarosławski, Chiraz Azaiez, Daria Korchagina, Mondher Toumi

Subjects: “…Orphan drugs…”
Get full text

A comparative study of orphan drug prices in Europe by Katherine Eve Young, Imen Soussi, Michiel Hemels, Mondher Toumi

Subjects: Get full text

Economics, externalities and rare disease by Carlisle Ford Runge, James Campbell, Carlisle P. Runge, Reena V. Kartha

Subjects: Get full text

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe by Goran Medic, Daria Korchagina, Katherine Eve Young, Mondher Toumi, Maarten Jacobus Postma, Micheline Wille, Michiel Hemels

Subjects: Get full text

Rare disease challenges and potential actions in the Middle East by Ahmad Nader Fasseeh, Nada Korra, Ahmed Aljedai, Ahmed Seyam, Hajer Almudaiheem, Hana A. Al-Abdulkarim, Marwan Janahi, Mary Gamal, Sahar Fahmy, Sara Aldallal, Sherif Abaza, Zoltán Kaló

Subjects: Get full text

Valuation of Medical Innovation Handling with Uncertainty and Risk by Mark Nuijten, Stefano Capri

Subjects: Get full text

Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop by Ghada Mohammed Abozaid, Ghada Mohammed Abozaid, Hussain Abdulrahman Al-Omar, Abdulaziz Alrabiah, Asma AlMuaither, Amy Jayne McKnight

Subjects: “…orphan drugs…”
Get full text

Non-profit drug research and development: the case study of Genethon by Szymon Jarosławski, Mondher Toumi

Subjects: Get full text

International experience in drug assessment for rare diseases: flexibility of approaches by K. S. Radaeva, A. S. Kolbin

Subjects: “…orphan drugs…”
Get full text

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration by Szymon Jarosławski, Pascal Auquier, Borislav Borissov, Claude Dussart, Mondher Toumi

Subjects: Get full text

APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES by V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova

Subjects: Get full text

Regulation of the Launch of Orphan Drugs on the Market of the Eurasian Economic Union as a Mechanism to Increase the Availability of Treatment for Rare Diseases (Review) by A. V. Foteeva, N. A. Koneva, O. S. Beloglazova, N. B. Rostova

Subjects: Get full text

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AND PROBLEMS OF RARE AND INTERDISCIPLINARY DISEASE by N. A. Shostak, A. A. Klimenko, N. A. Demidova

Subjects: Get full text

The clinical assessment of studies on orphan drugs in relation to the EMA’s authorization marketing decisions in Europe by Szczepan Jakubowski, Krzysztof Piotr Malinowski, Paweł Kawalec

Subjects: Get full text

Features of intellectual property protection mechanisms on the example of orphan drugs circulation by D. S. Yurochkin, К. V. Nasonova, Z. М. Golant, I. А. Narkevich, V. P. Trukhin

Subjects: Get full text